Investor Presentaiton

Royalty Pharma at a glance (1) Company 1996(2) Founded 66 Rare Disease Cancer (32%) Evrysdi Employees Trikafta Kalydeco Portfolio Orkambi Symdeko ~45 Oxlumo Approved and development-stage products Orladeyo 12 Crysvita $1bn+ blockbuster therapies in portfolio BCX9930 (24%) Trodelvy Xtandi Imbruvica Cabometyx Erleada CPI-0209 pelabresib Hematology (7%) Neurology (18%) Nurtec ODT Tysabri gantenerumab zavegepant seltorexant Cardio- Metabolic (13%) Farxiga Soliqua omecamtiv aficamten (4) Other Financial $2.1bn Adjusted Cash Receipts (3) (FY 2021) "top-line" $1.9bn Adjusted EBITDA (3) (FY 2021) $1.6bn Adjusted Cash Flow (3) (FY 2021) "bottom-line" Immunology (4%) Tremfya otilimab Entyvio 1. As of December 31, 2021, unless otherwise indicated; therapeutic area percentages based on Adjusted Cash Receipts in FY 2021. 2. Our predecessor was founded in 1996 and we were incorporated under the laws of England and Wales on February 6, 2020. We are externally managed by RP Management, LLC (the "Manager") and references to "employees" refer to such persons' role at the Manager. ROYALTY PHARMA 3. See slide 114 for definitions. Refer to the Appendix for a GAAP to non-GAAP reconciliation. 4. Royalty added January 2022 Promacta (2%) 5

View entire presentation